Scientific Programme

Thursday 11 April 2019

09.00   Registration Opens

11.00 – 11.10   Welcome Address
Christoph Zielinski, Vienna, Austria

11.10 – 11.30   Opening Lecture: Immunotherapy – next challenges of clinical drug development
Mario Sznol, New Haven, CT, USA

11.30 – 13.30 Plenary Symposium 1 – Microenvironment and metabolism

  • Imaging of T cell success and failure within the tumor microenvironment
    Emmanuel Donnadieu, Paris, France
  • Role of TGFß and CAFs in T cell exclusion”
    Eduard Batlle, Barcelona, Spain
  • Checkpoint inhibition and metabolic reprogramming
    Bo Huang, Beijing, China
  • Role of intratumoral memory T cells for immune surveillance
    Pedro Romero, Lausanne, Switzerland
  • Microbiota and its role for response to immunotherapy
    Lisa Derosa, Villejuif, France

13.30 – 14.30   Lunch

14.30 – 16.00   Plenary Symposium 2 – Emerging Concepts / New Agents

  • Targeting the CD73-adenosine axis for immunotherapy
    Paolo Ascierto, Naples Italy
  • Modulation of checkpoint antibodies
    Ana Anderson, Boston, MA, USA
  • Leukemic stem cells and immune evasion
    Claudia Lengerke, Basel, Switzerland
  • NK cells as target for therapeutic intervention
    Stéphanie Cornen, Marseille, France
  • The Siglec pathway – a target for improving T-cell activation
    Heinz Läubli, Basle, Switzerland
  • O1 – Aged neutrophils fuel tumor progression
    Christoph Reichel , Munich, Germany

16.00 – 16.30   Coffee Break

16.30 – 18.30   Plenary Symposium 3 – Combination Therapy

  • Rationales for combination strategies
    Samir Khleif, Augusta, GA, USA
  • Combination of checkpoint inhibition and vaccines
    Sjoerd van der Burg, Leiden, The Netherlands
  •  Interaction between cytokines and checkpoint inhibitors
    Aaron Ring, New Haven, CT, USA
  • Combination of Oncolytic Viruses and Checkpoint Inhibitors
    Alan Melcher, London, United Kingdom
  • Histon-Deacetylase inhibition in combination with immunotherapy
    Alfredo Budillon, Naples, Italy
  • O2 – Overall responses and survival in RCC on Pegilodecakin with anti-PD-1
    Aung Naing, Houston, TX, United States

18.30   Welcome Reception and Poster Viewing

 

Friday 12 April 2019

08.30 – 09.30   TNBC (Triple Negative Breast Cancer) Meet the Expert Session

09.30 – 10.30   Plenary Symposium 4 – Preclinical Models

  • Tumor organoids and immune cells
    Emile Voest,  Amsterdam, The Netherlands
  • Analysis of the tumor microenvironment by single cell analysis
    Bernard Thienpont, Leuven, Belgium
  • In vivo imaging of immune responses using PET-CT
    Angela Krackhardt, Munich, Germany

10.30 – 11.00   Coffee Break

11.00 – 12.40   Plenary Symposium 5 – Precision Medicine Meets Immunotherapy

  • Challenges of including immunobiomarkers into clinical drug development
    Jeffrey Weber, New York, NY, USA
  • Circulating tumor DNA as a tool to predict response in immunotherapy
    François-Clément Bidard, Paris, France
  • T Cell subpopulations predict response to combination of PD-L1 blockage and chemotherapy
    Barbara Seliger, Halle, Germany
  • Prediction of efficacy and toxicity of immunotherapeutic agents
    Lei Zheng, Baltimore, MD, USA
  • System immunology and tumor microenvironment
    Jérôme Galon, Paris, France
  • O3 – A plasma-based assay for assessment of tumour mutational burden in patients with metastatic non-small cell lung cancer in the first-line treatment setting: results from the MYSTIC study
    Han Si, Gaithersburgh, MD, United States
  • O4 – Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in non-small cell lung carcinoma patients responding to atezolizumab treatment
    Alessandra Nardin, Singapore, Singapore

12.45 – 13.15   Exhibitors (Pipeline) Session

  • FLUIDIGM
    “Define the Tumor Microenvironment with CyTOF® technology and microfluidics solutions”
    Roberto Spada, Business Development Specialist, Mass Cytometry, Fluidigm
    Fluidigm enables the comprehensive cellular and molecular profiling of the immune system and the tumor microenvironment with proven mass cytometry, Imaging Mass Cytometry™ (IMC™) and automated microfluidics solutions.  By measuring >37 protein markers in cells or tissue, CyTOF technology enables the classification of phenotype and function from PBMCs to FFPE tissue sections with single cell resolution.  With our integrated fluidic circuit (IFC) technology, gene expression profiling of the immune system can be performed swiftly and cost-effectively in nanoscale reaction chambers. Whether you seek to target new biomarkers and pathways or to optimize the effectiveness of checkpoint inhibitors, CAR T cells or cancer vaccines, Fluidigm can help you identify new insights to reach your next research breakthrough. 
  • NANOSTRING
    “Discovery of candidate predictive biomarkers for therapeutic response to immune checkpoint inhibitors in melanoma.”
    Douglas Hinerfeld, PhD. Principal Product Application Scientist. Nanostring Technologies
    Significant progress has been made in the development of molecular diagnostics to predict therapeutic response to immune checkpoint inhibitors (ICI) in melanoma, however there remain many patients whose response is not accurately predicted.  Stimulated by this challenge, we have collaborated with Dr. David Rimm at Yale University to evaluate the application of high plex spatially resolved protein analysis in FFPE specimens using GeoMx® Digital Spatial Profiling (DSP) to the discovery of candidate biomarkers for ICI response in melanoma.  Using DSP, we have analyzed the spatial expression of 44 immune-related proteins across 60 ICI-treated patients. The expression patterns of a subset of the proteins were first validated through comparison to Quantitative Immunofluorescence. DSP analysis identified multiple markers that were predictive of prolonged progression free and/or overall survival.  This study exemplifies the power of high-plex protein analysis in FFPE tumor specimens in the context of therapeutic response.

13.15 – 14.00   Lunch

 14.00 – 14.30   Poster Viewing with Presenters

14.30 – 15.15   Lifetime Achievement Award

  • Innate Immunity, Inflammation and Cancer: from bench to bedside
    Alberto Mantovani, Milan, Italy

15.15 – 15.45   Coffee Break

15.45 – 17.15   Plenary Symposium 6 – Cell Therapy

  • Next generation cell therapies
    Lisa Butterfield, San Francisco, CA, United States
  • TRUCKs
    Hinrich Abken, Regensburg, Germany
  • Synthetic agonist receptor modified T cells: a new modular platform for T-cell therapy
    Sebastian Kobold, Munich, Germany
  • CAR-NK cell therapy
    Ulrike Koehl, Leipzig, Germany
  • O5 – Characterization of bispecific antibodies that drive synthetic agonistic receptor – transduced T Cells to mediate specific and conditional therapy in human pancreatic cancer models
    Mohamed-Reda Benmebarek, Munich, Germany

17.15 – 17.55   Plenary Session 7Young Researcher Session

  • O6 – A screening for novel immune-checkpoints identifies a serine/threonine kinase to confer Immune  resistance in multiple myeloma
    Valentina Volpin, Regensburg, Germany
  • O7 – Immune and mutational landscape in triple negative breast cancer and its evolution during neoadjuvant chemotherapy associated or not with GTN and anti-PD-1
    Nesrine Mabrouk, Dijon, France
  • O8 – In-situ diversification of immunity following vaccination targeting tumor neoepitopes; an integral component of combinatorial immunotherapy
    Karin Lee, Bethesda, MD, United States
  • O9 – Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis
    Julijan Kabiljo, Vienna, Austria

19.30   ITOC6 Conference Dinner

 

Saturday 13 April 2019

08.30 – 09.30   Plenary Session 8Anticancer Vaccines

  • Challenges of anticancer vaccine development
    Cornelis Melief, Leiden, The Netherlands
  • Mimotopes  for Vaccination against Cancer
    Ursula Wiedermann-Schmidt, Vienna, Austria
  • Neoantigen vaccination
    NN

09.30 – 11.10    Plenary Symposium 9 – Clinical Breakthrough with Immunotherapy – Part 1
Joint Session with ESMO

  • Immune related adverse events
    Michael von Bergwelt, Munich, Germany
  • Cell Therapy
    John Haanen, Amsterdam, The Netherlands
  • Checkpoint inhibition in hematological malignancies
    Dominik Wolf, Innsbruck, Austria
  • NSCLC
    NN
  • Melanoma
    NN

11.10 – 11.40     Coffee Break

11.40 – 12.40     Plenary Symposium 9 – Clinical Breakthrough with Immunotherapy – Part 2
Joint Session with ESMO

  • Microsatellite Instability +/- GU
    NN
  • Renal Cancer
    Paul Nathan, London, United Kingdom
  • Head & Neck
    Marco Merlano, Cuneo, Italy

12.40 – 13.00   Best Poster Awards & Closing Remarks

13.00 – 14.00       Lunch